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INCIDENCE OF HPV INFECTION IN HIGH AND LOW GRADE 
LESIONS OF CERVIX 
INTRODUCTION 
Carcinoma of the uterine cervix is the most common cancer in South Indian 
women and occupies the top rank among cancers in women in most 
developing countries, constituting 34% of all women’s cancers. To an 
estimated annual global incidence of 500,000 cervical cancers, India 
contributes 100,000, ie. 1/5 of the world burden.23 The magnitude of the 
problem is thus more than evident. The world pattern of cervical cancer, 
together with the age adjusted rate and ranking, clearly indicate that cervical 
cancer is predominantly a problem of poorer socio-economic societies.1  
On the other hand, uterine cervical cancer is a favourable site for an effective 
control program. It is easily accessible and there is usually a long latent period 
of intraepithelial neoplasia which is easily recognizable by the Pap smear. 
Furthermore, treatment at this stage is very effective.  
The burden of cervical cancer in India, taken in the context of the additional 
problems of advanced disease at presentation, the country’s limited resources 
and health infrastructure, and the paucity of trained personnel emphasize the 
urgent need for a control program.  
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Cancer of the cervix has been the most important problem  in women in India 
over the past two decades. 
The first IARC-sponsored case control study on HPV and cervical cancer in 
India, which was carried out at the Cancer Institute, Chennai, documented that 
99% of uterine cervical cancers were HPV-positive compared to only 22% in 
the controls. 
Preventive vaccination is under intensive study.  
Accepted methods for early cervical cancer detection and control for a 
developing environment include:  
1. Education; access to health care 
2. Unaided visual inspection and clinical downstaging 
3. Aided Visual Inspection (VIA)24  
4. VIA with magnification (VIAM) 
5. HPV testing 
Ref Cytology Uni. of Zimbabwe/JHPIEGO Cervical Cancer Project Visual 
inspection with acetic acid for Cervical Cancer Screening Lancet 1999, 
353, 869-73 
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 Four of the five districts in India were Cancer Cervix is very much prevelant 
are concentrated in the north eastern 
region of Tamil Nadu state and Puducherry. 
Ref. Annual Report, 1982, National Cancer Registry, New Delhi: Indian 
Council of Medical Research; 1985. 
WHO  has stated in studies that “ Quite often,a considerable discussion is 
focused on which screening test to use ¾ cytology or alternatives to cytology, 
such as VIA or HPV testing  or which combinations/sequence of screening 
tests should be used for screening in developing countries. Choosing a suitable 
screening test is only one aspect of a screening programme”32 
 
Screening for cancer cervix forms an important way of preventing the 
disease.HPV DNA assay is the most sensitive test among the screening 
methods.This study is the detection of the HPV infection among low and high 
grade lesions.HPV infection has a long latency period even before the visible 
precancerous lesions which makes the test the best screening method. 
 
In developing countries like India, there is a lack of effective screening 
programs for cervical cancer. In these countries, no clinically significant 
reduction in the incidence of cervical cancer has occurred during the past three 
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decades.19,20,21,22 In developed countries, by contrast, there has been a major 
decline in cervical-cancer mortality after the introduction of large-scale 
cytologic testing. The limited success of such screening in developing 
countries has stimulated evaluation of testing for human papillomavirus 
(HPV). 
Sensitivity = 93.0% 95% CI = 84.3 to 97.7 
Specificity = 61.1%  
95% CI = 57.7 to 64.4 
Disease Prevalence = 8.0%  
Assay Positive Predictive Value = 17.2%  
Assay Negative Predictive Value = 99.0% 
 
The Utility of HPV DNA Testing for Triage of Women with 
Borderline Pap Smears was conducted in 1996 under the direction of the 
Kaiser Foundation Research Institute and the Kaiser Permanente Medical 
Group. 
HPV VIRUS: 
 
      Human papillomaviruses are composed of an 8000 base pair double-
stranded circular DNA molecule surrounded by a protein capsid. 
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LIFECYCLE OF HPV: 
The HPV lifecycle strictly follows the differentiation program of the host 
keratinocyte. The HPV virion infects epithelial tissues through micro-
abrasions, whereby the virion associates with putative receptors such as alpha 
integrins and laminins, leading to entry of the virions into basal epithelial cells 
through clathrin-mediated endocytosis and/or caveolin-mediated endocytosis 
depending on the type of HPV. At this point, the viral genome is transported 
to the nucleus by unknown mechanisms and establishes itself at a copy 
number between 10-200 viral genomes per cell. A sophisticated 
transcriptional cascade then occurs as the host keratinocyte begins to divide 
and become increasingly differentiated in the upper layers of the 
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epithelium.
 
 
E6/E7 proteins 
The viral oncogenes, E6 and E7 modify the cell cycle so as to retain the 
differentiating host keratinocyte in a state that is favorable to the amplification 
 7
of viral genome replication and consequent late gene expression. E6 in 
association with host E6 AP (associated protein), which has ubiquitin ligase 
activity act to ubiquitinate p53 leading to its proteosomal degradation. E7 (in 
oncogenic HPVs) acts as the primary transforming protein. E7 competes for 
retinoblastoma protein (pRb) binding, freeing the transcription factor E2F to 
transactivate its targets, thus pushing the cell cycle forwards. All HPV can 
induce transient proliferation, but only 16 and 18 can immortalize cell cycle 
(in vitro). In the upper layers of the host epithelium, the late genes L1 and L2 
are transcribed/translated and serve as structural proteins which encapsidate 
(Encapsidation is the process of incorporating a nucleic acid sequence (e.g., a 
vector, or a viral genome) into a viral particle) the amplified viral genomes. 
Once the genome is encapsidated, the capsid appears to undergo a redox-
dependent assembly/maturation event which is tied to a natural redox gradient 
that spans both suprabasal and cornified epithelial tissue layers. This 
assembly/maturation event stabilizes virions, and increases their specific 
infectivity. Virions can then be sloughed off in the dead squames of the host 
epithelium and t the viral lifecycle continues. 
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HPV TO CANCER LATENCY PERIOD 
Once an HPV virus invades a cell, an active infection occurs, and the virus 
can be transmitted. Several months to years may elapse before squamous 
intraepithelial lesions (SIL) develop and can be clinically detected. 
 
 
 
 9
Carcinogenic and possibly carcinogenic types of HPV 
Carcinogenic types 
Species 9: 16, 31, 33, 35, 52, and 58 
Species 7: 18, 39, 45, 59, and 68 
Species 5: 51 and 82 
Species 6: 56 
Species 11: 73 
Possibly carcinogenic types 
Species 11: 53 
Species 5: 26 
Species 6: 66 
HPV types and associated diseases  
 
Notable HPV types and associated diseases 
Over 100 different HPV types have been identified and are referred to by 
number. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are "high-
risk" sexually transmitted HPVs and may lead to the development of cervical 
intraepithelial neoplasia (CIN) and vulvar intraepithelial neoplasia (VIN). 
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Disease HPV type 
Common warts 2, 7 
Flat warts 3, 10 
Anogenital warts 6, 11, 42, 44 and others 
Genital cancers 
• Highest risk : 16, 18, 31, 45 
• Other high-risk: 33, 35, 39, 51, 52, 56, 58, 59 
• Probably high-risk: 26, 53, 66, 68, 73, 82 
 
 
HPV types 16 and 18 together cause about 70 percent of cervical cancers. It is 
important to note, however, that the great majority of high-risk HPV 
infections go away on their own and do not cause cancer. 
In 2006, the U.S. Food and Drug Administration (FDA) approved Gardasil, a 
vaccine that is highly effective in preventing infection with types 16 and 18, 
two “high-risk” HPVs that cause most (70 percent) cervical cancers and types 
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6 and 11, which cause most (90 percent) 
HPV testing for cervical HPV infection 
HYBRID CAPTURE TEST: 
In March 2003, the US FDA approved the Digene HPV HC2 DNA Test; a 
"hybrid-capture" test manufactured by Qiagen, as the primary screening tool 
for detecting HPV cervical infection as an adjunct to Pap testing, and may be 
performed during a routine Pap smear. It can detect the DNA of the 18 HPV 
types that most commonly affect the cervix and distinguish between "low" 
and "high-risk" HPV types, but it cannot determine the specific HPV types. 
It is performed by collecting cells from the cervix and then sending them to a 
laboratory for analysis. The test can detect high-risk types of HPV even before 
there are any conclusive visible changes to the cervical cells. 
 
 The collection technique is similar to that of a Pap smear: remove excess 
mucous, insert a brush 1 to 1.5 cm into the cervical os, make three full turns in 
a counter-clockwise direction,insert the brush to the bottom of the transport 
tube, snap off the shaft, carefully cap the tube, and ship the tube at room 
temperature within two weeks. 
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THE HC2 High-Risk HPV DNA Test using capture 2 technology is a nucleic 
acid hybridization assay with signal amplification that utilizes microplate 
chemiluminescent detection. Specimens containing the target DNA hybridize 
with a specific HPV RNA probe. The resultant RNA:DNA hybrids are 
captured onto the surface of a microplate well coated with antibodies specific 
for RNA:DNA hybrids.several alkaline phosphatase molecules are conjugated 
to each anti body. As the substrate is cleaved by the bound alkaline 
phosphatase, light is emitted which is measured as relative light units on a 
luminometer. 
An RLU measurement equal to or greater than the cutoff value indicates the 
presence of high-risk HPV DNA sequences in the specimen. High volume 
sample-throughput testing with the hc2 High-risk HPV DNA Test can be 
performed utilizing the rapid capture system (RCS). To enable high volume 
sample-throughput testing, all the procedural steps of the assay are performed 
by the RCS, with the exception of specimen denaturation, chemiluminescent 
signal detection, and result reporting. 
HPV DNA can also be detected by PCR with the use of generic or consensus 
primers. This technique is more sensitive than the Hybrid Capture hc2 assay, 
allowing identification of specific HPV types and variants.8, 13, 18–20 it 
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awaits final clinical validation. Both techniques are amenable for high-
throughput, rapid, automated testing (e.g., Hybrid Capture can test up to 96 
samples in less than 2 h).  
 
The recent outcomes in the identification of molecular pathways involved in 
cervical cancer provide helpful information about novel bio- or oncogenic 
markers that allow monitoring of these essential molecular events in 
cytological smears, histological or cytological specimens. These bio- or onco- 
markers are likely to improve the detection of lesions that have a high risk of 
progression in both primary screening and triage settings. E6 and E7 mRNA 
detection PreTect HPV-Proofer, (HPV OncoTect) or p16 cell-cycle protein 
levels are examples of these new molecular markers. According to published 
results these markers, which are highly sensitive and specific, allow to 
identify cells going through malignant transformation 
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OTHER METHODS OF SCREENING FOR CANCER CERVIX: 
 
PAP SMEAR 
 The Pap smear is the mainstay of primary screening for cervical cancer.  It 
should be performed with a cervical broom turned three times in a counter-
clockwise fashion or with both an endocervical brush turned three times and 
along-tipped Ayres’s spatula rotated once on the os of the cervix. Excessive 
mucous on the cervix should be cleaned off before the specimen is taken. The 
specimen can be put in a liquid specifically designed for LBC or can be 
smeared on a glass slide. If a broom is used, the secretions should be stroked 
once across the slide. If a brush and spatula are used, the brush should be 
unrolled on the upper part of the slide from left to right, and the spatula should 
be stroked on the lower part of the slide from left to right, without returning 
on the smeared material. 
 15
 
 
KOILOCYTE 
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The major system used to report the results of Pap tests in the United States is 
the Bethesda System. In this system, samples with cell abnormalities are 
divided into the following categories: 
• ASC—Atypical Squamous Cells. Squamous cells are the thin, flat cells that 
form the 
surface of the cervix. The Bethesda System divides this category into two 
groups: 
1. ASC–US—Atypical Squamous Cells of Undetermined Significance. The 
squamous cells do not appear completely normal, but are uncertain what the 
cell changes mean. Sometimes the changes are related to HPV infection.  
2. ASC–H—Atypical Squamous Cells cannot exclude a High-grade squamous 
intraepithelial abnormality.  ASC–H may indicate a higher risk of 
being precancerous compared with ASC–US. 
• AGC—Atypical Glandular Cells. Glandular cells are mucus-producing cells 
found in 
the endocervical canal  or in the lining of the uterus.  
• AIS—endocervical Adenocarcinoma In-Situ. Precancerous cells are found in 
the 
 17
glandular tissue. 
Pap test results may also be described using an older set of categories called 
the “dysplasia scale.”  
There are four degrees of dysplasia: mild, moderate, severe, and carcinoma in 
situ.Carcinoma in situ is a precancerous condition that involves only the layer 
of cells on the surface of the cervix, and has not spread to nearby tissues. In 
the Bethesda System, mild dysplasia is classified as LSIL; moderate or severe 
dysplasia and carcinoma in situ are combined into HSIL. 
Cervical intraepithelial neoplasia (CIN) is another term that is sometimes used 
to describe abnormal tissue findings. Neoplasia means an abnormal growth of 
cells. The term CIN along with a number describes how much of the thickness 
of the lining of the cervix contains abnormal cells. CIN–3 is considered to be 
a precancerous condition that includes carcinoma in situ. 
 Tests used to screen for and diagnose precancerous cervical conditions 
A Pap test is the standard way to check for any cervical cell changes. A Pap 
test is usually done as part of a gynecologic examination. 
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COLPOSCOPIC PICTURE OF LSIL 
LSIL is a low grade lesion with a faint acetowhite areas in colposcopy and are 
classified as mild dysplasia or CIN 1. 
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 20
 
 
 
 
• HSIL—High-grade Squamous Intraepithelial Lesion. HSILs are more 
severe abnormalities and may eventually lead to cancer if left untreated. 
COLPOSCOPIC PICTURE OF HSIL 
 21
 
 
REVIEW OF LITERATURE 
 
Cuzick et al 1 evaluated 2009 women with both pap and HPV PCR for HPV 
SEROTYPES 16, 18, 31, and 33.Women were referred for colposcopy for any 
degree of dysplasia and/or appositive HPV test.A total of 231 women 
underwent colposcopy.Using a threshold of mild degree or greater as a 
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reference standard, the sensitivity of HPV testing for identifying high risk 
types was 75%.1 
  
Clavel et al 2 used the HC 2 assay in conjunction with cytology in studing 
1627 samples.For the detection of biopsy- confirmed high grade lesions, the 
sensitivity of HPV testing was 98.1%2.  
Kuhn et al 3 studied 2944 previously unscreened women using sequential 
cytology, the HC assay, cervical inspection, and 
cervicography.conclusion:The sensitivity of HPV testing was superior 
(88.4%) to that of other methods3. 
 
Elfgren K4, Rylander E, Rådberg T, Strander B, Strand A, Paajanen K, 
Sjöberg I, Ryd W, Silins I, Dillner J; Swedescreen Study Group conducted a 
Randomized Controlled trial about the Colposcopic and histopathologic 
evaluation of women participating in population-based screening for human 
papillomavirus deoxyribonucleic acid persistence.conclusion:70% of women 
with abnormal colposcopic lesions show positive for HPV infection. However 
90% of them regressed over the next 2 years4.   
Kaufman RH5, Adam E, Icenogle J, Lawson H, Lee N, Reeves KO, Irwin J, 
Simon T, Press M, Uhler R, Entman C, Reeves WC evaluated 1128 women 
 23
and studied the Relevance of human papillomavirus screening in management 
of  CIN5. 
Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, 
Gabriel R, Quereux C, Birembaut P conducted a preliminary study on 1518 
women to detect in routine high-grade cervical lesions human papillomavirus 
by Hybrid Capture II-based detection6. 
In a study of women with invasive cervical cancer, and matched controls, 
from four high risk areas in Panama) Mexico, Costa Rica and Columbia HPV 
16 or HPV 18 was detected in 62% of 759 case patients and 32% of 1430 
controls. The relative risk increased with increasing HPV DNA copy num-
ber.68 such case-control studies are complicated by a series of variables, not 
the least of which is the number of sexual partners7. 
        Correlation between HPV presence and coital factors was disputed by 
Hording et al who compared Greenlandic and Danish women. Greenland has 
one of the highest incidences of cervical cancer in the world, more than five 
times higher than Denmark. Greenlandic women commence sexual activity at 
a significantly younger age and are more likely to have more than 20 lifetime 
partners (53%) when compared with their Danish counterparts (4%). Despite 
these behavioural differences, HPV 16 DNA was found in a similar incidence 
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(55% vs. 45%) in Greenlandic and Danish'women with cervical cancer8.  
Campion et al8 reviewed 26 women who progressed to CIN 3 after initial 
evidence of mild atypia or dyskaryosis; 85% of those progressing had HPV 16 
DNA, compared to the original group9. 
 
 Lorincz et al 9 reported on 398 women, seen in a private gynaecology clinic, 
who had HPV presence assessed by Southern blot hybridisation of cervical 
samples obtained from swabs. Women with normal smears were followed up 
for an average of 2 to 3 years by further smears; among those who originally 
had HPV 15% developed cytological changes consistent with cervical 
intraepithelial neoplasia compared with 5% who were HPV negative.Ref 
Lorincz A T,Schiffman M H , Jauffer W J etal. Temporal association of 
HPVB with cervical cytologic abnormalities10.  
Similarly Koutsky et al followed a cohort of 241 women with normal smears 
using dot-filter hybridisation at 4 monthly intervals; the 2 year cumulative 
incidence of CIN 2-3 from the time of first positive test for HPV DNA was 
28% compared with 3% if the smear remained HPV negative11. 
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 Young et al 10 reported that of 38 women with an abnormal smear 36 had 
HPV 16 and 22 had both HPV 16 and HPV 11. However, 7 of 10 women with 
a normal smear also tested positive for HPV 16 or HPV 11 DNA12. 
 
Tidy et al 11 reported that 67% of dyskaryotic smears contained HPV 16, and, 
if carcinoma was present the figure rose to 100%. Again, 117 of 140 (84%) of 
the normal smears were also positive. He detected by PCR13. 
Macnab et al 12 found that 84% of cervical and vulval carcinoma contained 
HPV 16 DNA, but also found" the virus DNA in 73% of histologically normal 
control tissue adjacent to the lesion. This control tissue was taken from the 
uterus at radical hysterectomy or from a strip of abdominal wall skin superior 
to the transverse abdominal incision at radical vulvectomy and at least 2 cm 
from the nearest tumour edge. When specimens of ectocervical epithelium 
taken at hysterectomy performed for non-neoplastic conditions 
were'examined, only 11% contained HPV 16 DNA14. 
 Meanwell et alsl 13 found HPV 16 DNA in 35% of women with normal 
cervical smears. They, however found no evidence of virus DNA integration, 
whereas Macnab's group32 detected HPV DNA integrated within host 
chromosome and surprisingly, sometimes present in higher viral copy 
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numbers in normal tissue than in the neoplastic tissue15.  
. Kitchener et al"  studied a series of sexually active women, recruited at a 
Family Planning Clinic, with a routine cervical smear in which koilocytosis 
suggested the presence of HPV infection but the absence of dyskaryosis. 10% 
of the women had HPV 16 DNA in tissue taken from the transformation zone, 
and some had HPV 16 in the apparently normal adjacent squamous 
epithelium16. 
                 Syrjane et al  15 found progression to  CIN 3  from lowgrade 
lesions in 66 of 508 women (12.9%) during a mean follow up period of 35 
months, where HPV 6 and HPV 11 were found as  frequently as HPV 16 and 
HPV1817. 
Portland Kaiser Permanente studies allowed researchers to examine whether 
testing for specific human papilloma virus (HPV) types—HPV16 and 
HPV18—were more effective at predicting risk for precancerous conditions or 
cervical cancer than testing for a broad pool of cancer-causing, or oncogenic, 
HPV types. The study authors found that women who tested positive for 
HPV16 or HPV18 had an increased risk for precancerous conditions and 
cervical cancer compared to those women who tested negative for HPV)18.  
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In October 1999,  Sankaranarayanan  et al 16 initiated a cluster-randomized, 
controlled trial to evaluate the effectiveness of a single round of HPV testing, 
cytologic testing, or VIA in reducing the incidence of cervical cancer, as 
compared with a control group that received usual care in a previously 
unscreened, high-risk population in the Osmanabad district in the state of 
Maharashtra, India. They reported the cervical-cancer incidence and mortality 
in the four groups after 8 years of follow-up. They found that HPV testing was 
the most objective and reproducible of all cervical screening tests and was less 
demanding in terms of training and quality assurance. In low-resource settings 
with no capacity for colposcopy and histopathological analysis (e.g., many 
countries in sub-Saharan Africa), HPV-positive women without clinical 
evidence of invasive cancer could receive immediate treatment, such as 
cryotherapy. However, since most HPV infections in young women regress 
rapidly without causing clinically significant disease, such an approach raises 
a legitimate concern. Hence, HPV testing should not be used for primary 
screening of women under 30 years of age19. 
Against the prevailing view during the 1970s, Harald zur Hausen 17 
postulated a role for human papilloma virus (HPV) in cervical cancer. He 
assumed that the tumour cells, if they contained an oncogenic virus, should 
harbour viral DNA integrated into their genomes. The HPV genes promoting 
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cell proliferation should therefore be detectable by specifically searching 
tumour cells for such viral DNA20.  
Sowjanya 18 AP, Jain M, Poli UR, Padma S, Das M, Shah KV, Rao BN, Devi 
RR, Gravitt PE, Ramakrishna G. Centre for DNA Fingerprinting and 
Diagnostics, Hyderabad, A.P. India. conducted a study about the Prevalence 
and distribution of high-risk human papilloma virus (HPV) types in invasive 
squamous cell carcinoma of the cervix and in normal women in Andhra 
Pradesh, India21. 
 Cherian Verghese OF Trivandrum Kerala conducted a study about the 
prevalence of HPV in high risk cervical lesions in Kerala.conclusion: is as 
follows the over all prevalence rate is 7% with higher prevalence among low 
SES,women of poor education,early age of marriage and husbands of women 
with multiple sexual partners22.   
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STUDY 
AIM OF THE STUDY : 
To determine the  HPV status in high and low grade cervical lesions in women 
of reproductive age group . 
SETTING: 
It is a prospective study conducted in the Institute of Social Obstetrics (ISO) 
& Govt. Kasturba Gandhi Hospital for Women and Children, Triplicane. 
Chennai attached to the Madras medical College, Chennai. 
SAMPLE SIZE: 
IT is conducted in a sample of 50 women with high risk cervical lesions 
during the period 2008-2009 . 
Around 350 women in the reproductive age group are screened in the 
colposcopy clinic and among them 50 are selected for HPV testing. 
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MATERIALS AND METHODS : 
THE HC2 High-Risk HPV DNA Test using capture 2 technology is a nucleic 
acid hybridization assay with signal amplification that utilizes micro plate 
chemiluminescent detection. 
It is a solution phase hybridization assay which results in HPV DNA signal 
amplification. 
All my tests are done in the Lab of RENU DIAGNOSTICS. 
 
The kit is an in vitro nucleic Acid Hybridization Microplate Assay with 
Amplification using Microplate chemiluminescene for the Qualitative 
Detection of 13 High-Risk types of human papillomavirus (HPV) DNA in 
cervical Specimens.  It is a DNA PAP Cervical Sampler. 
The Manufacturers are DIEGENE, 1201, Clopper road, Gatheisberg, USA. A 
R Med Limited. 
Samples are collected by cervical brushings   in liquid media and subjected to 
the test 
The assay uses RNA probes that react with 13 DNA targets 
These RNA-DNA hybrids are captured by monoclonal antibodies bound to the 
well plate and detected with anti hybrid antibodies by chemiluminesence. 
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Step 1Denature DNA [~1 hour]To initiate the lab process (labeling tubes for 
identification, etc.).  
1. Cervical specimen is added to sample tube. 
2. Denaturation agent is added to tube. 
Step 2: Mixing of probes and hybridization [~1.5 hours] 
1. Probe B cocktail for the high-risk HPV types is prepared and Added to 
the Tubes. (Probe B is specific for oncogenic HPV types.) 
2. The tubes are placed in a water bath at 65°C for 30 minutes.  
3. The samples are washed  several times using a standard laboratory 
reagent. 
Step 3: Hybrid capture [~1.5 hours] 
1. The processed samples are transferred to a microtiter plate provided in 
the kit. 
2. It is placed on a mechanical shaker for 30 minutes (allowing the RNA-
DNA hybrids created in Step 2 to be “captured” by antibodies attached 
to the walls of the microtiter well). 
Step 4: Detection for labeling [~1 hour] 
1. Additional antibodies tagged with alkaline phosphate, are added which 
bind with the captured materials from Step 3. When the alkaline 
phosphatase separates from the antibody complex, light is produced. 
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Step 5: Detection, validation, and interpretation [~1 hour] 
2. The light released during Step 4 is measured using a luminometer with 
integrated computer software. Any sample that emits light as bright as 
or brighter than the light released by a positive control is considered a 
positive signal for HPV. 
INCLUSION CRITERIA: 
 
Women in the age group 25-35 yrs 
Women who are leading an active sexual life 
Women who have  HSIL  and HSIL in colposcopic findings . 
 
 
 
 
EXCLUSION CRITERIA: 
 
Post menopausal women 
Who are not leading an active sexual life 
Invasive cancer cervix 
Normal colposcopic findings 
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Women with gross active PID or cervicitis 
 
FOLLOW UP: 
 
HPV testing is either coded positive or negative. 
The results are expressed as a ratio of the specimen strength in relative light 
units (RLU) to the concurrently tested 1pg/ml HPV DNA controls. 
HPV positive patients are followed up with colposcopic examination and 
repeat testing after 6months. 
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RESULTS AND ANALYSIS 
 
 
TABLE1 
 
 
The study group involves reproductive age group women who are leading 
an active sexual life. 
 Frequency Percent 
25 to 30 
31 to 35 
Total 
33 
17 
50 
66.0 
34.0 
100.0 
AGE GROUP
31 to 35
25to30 
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66% were in 25 to 30yrs age group. 
34% were in 31 to 35yrs age group. 
 
1-P1  2-P2  3-P3 
 
TABLE 2 
  Frequency Percent 
 1.00 4 8.0
2.00 37 74.0
3.00 9 18.0
Total 50 100.0
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The distribution of parity among the study group were 
P1 and P2 82% 
P3 18%.Most of the study population were multi parous women. 
 
 
CONTRACEPTION 
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TABLE 3  
 
 
 
84% of study population was sterilized by Puerperal Sterilization. 
8% used IUCDs. 4% each used barrier and OCPs. 
 
  Frequency Percent 
 1 PS 42 84.0 
2 BARRIER 2 4.0 
3 OCP 2 4.0 
4 IUCD 4 8.0 
Total 50 100.0 
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SES GROUP
3.00
2.00
1.00
 
 
1income Rs1500PM and 2 income Rs2000PM 
3 income≥ Rs 3000 PM. 
 
82% belong to income ≤ Rs 2000 
18% belong to income ≥Rs3000 
 
 
 
TABLE 4 
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  Frequency Percent 
 1.00 16 32.0
2.00 25 50.0
3.00 9 18.0
Total 50 100.0
 
                                        
AGE OF MARRIAGE 
 
80%  of the study group had consummation of marriage before 22 yrs. 
20% were in 23 to 25 yrs age group. 
 40
 
 
 
 
 
 
 
TABLE 5      
 AGE Frequency Percent 
 18.00 7 14.0 
19.00 4 8.0 
20.00 13 26.0 
21.00 8 16.0 
22.00 8 16.0 
23.00 4 8.0 
24.00 2 4.0 
25.00 4 8.0 
Total 50 100.0 
 41
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1-< 5th std 
2 -5th to 10th std 
3-> 10th std  
 
84% were studied below 10th std. 
16%studied above 10th std. 
 
 
 
 
 
 
 
 
 
 
EDUCATION 
TABLE 6 
EDUCATION VALID PERCENT 
UP TO 5th STD 20 24 
 43
5th TO 10th  22 68 
ABOVE 10th STD 8 8 
TOTAL                             50                                      100 
 
 
 
1
-LSIL 
2- HSIL 
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TABLE 7 
COLPOSCOPY 
 
FREQUENCY PERCENT 
LSIL 
 
41 82 
HSIL 9 18 
TOTAL 
 
50 100 
 
82% of study population had LSIL and 18% of study population had HSIL as 
their colposcopic findings. 
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TABLE 8 
HPV TESTING 
 
FREQUENCY PERCENT 
POSITIVE 
 
17 34 
NEGATIVE 
 
33 66 
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66% Of colposcopic lesions (LSIL and HSIL)were positive for HPV 
testing. 34% of lesions were negative for HPV testing. 
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AGE & HPV TESTING 
 
 
1-HPV POSITIVE 
 48
2-HPV NEGATIVE 
 
                                            
TABLE 9 
                                     HPV TESTING 
AGE GROUP NEGATIVE POSITIVE TOTAL 
25 TO 30 11 22 33 
31 TO 35 6 11 17 
TOTAL 17 33 50 
 
66% of HPV positive population falls in the age group 25 to 30 years. 
The peak incidence of HPV is between 28 to 30 yrs of age group. 
 
The incidence of HSIL and LSIL among different age groups 
TABLE 10 
AGE GROUP HSIL LSIL TOTAL 
25 TO 30 7 29 36 
31 TO 35 2 12 14 
TOTAL 9 41 50 
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. 
 
 
 
 
The LSIL and HSIL  lesions show peak incidence between age groups 25 to 
30 years. 
 
 
 
0
5
10
15
20
25
30
25 TO 30 31 TO 35
HSIL
LSIL
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1income ≥ Rs 3000 PM . and 2 income Rs2000PM 
3 income Rs1500PM 
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TABLE 11 
 52
HPV TEST 
SES/INCOME PM NEGATIVE POSITIVE 
≥ Rs 3000 . 8 8 
Rs 2000 7 18 
Rs1500 2 7 
TOTAL 17 33 
 
The study is conducted mainly in low socio economic group.88% of the study 
population with income<RS2000 were positive for HPV. Among income 
group ≥ Rs 3000 PM HPV positivity is 50%.HPV infection is prevalent 
among low socio economic status. 
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EDUCATION 
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TABLE 12 
HPV TEST 
EDUCATION NEGATIVE POSITIVE 
1-NIL 10 10 
2-<5th STD 5 17 
3- 5th to 10th STD 2 6 
TOTAL 17 33 
 
EDU. GROUP
3.002.001.00
Count
20 
10
0
HPV TESTING
     NEG
    POS
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The HPV infection is increased among illiterate women and who are studied 
less. My study is conducted more on women who are studied less than high 
school 
 
 
 
 
 
 
 
 
 
 
 
                                   
  AGE OF MARRIAGE 
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TABLE 13 
                                                          HPV TEST 
AGE OF MARRIAGE NEGATIVE POSITIVE 
2 < 20 YRS 6 20 
 57
1 20 to 25 YRS 11 13 
TOTAL 17 33 
 
 
Earlier is the age of marriage the HPV infection rate is high.77% of those 
who are married < 20 yrs got infected  with HPV where as only 50% of 
those who are married >21 yrs got infected with HPV. 
 
 
PARITY 
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                                                                       TABLE 14       
                                                                       HPV TEST 
PARITY NEGATIVE POSITIVE 
P1 2 2  
P2 13 24 
P3 2 7 
TOTAL 17 33 
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The infection rate is high among multiparous women. 
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1-HPV POSITIVE 
2-HPV NEGATIVE 
 
 
                                        TABLE 15 
HPV TEST 
CONTRACEPTION NEGATIVE POSITIVE 
PS 14 28 
BARRIER 1 1 
OCP 1 1 
IUCD 1 3 
TOTAL 17 33 
 
The HPV positivity is increased among the population who had 
undergone PS and are using IUCDs.Women who were using Barrier 
methods of contraception and OCPs show less positivity compared to 
others. Women who used OCPs also used barrier methods in between in 
my study group. 
 
1 PS 
2 
BARRIE
R 
3 OCP 
4 IUCD 
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SMOKING AND HPV: 
TABLE 16 
                                            HPV TEST 
SMOKING POSITIVE NEGATIVE 
PRESENT 28 7 
ABSENT 5 8 
 
0
5
10
15
20
25
30
POSITIVE NEGATIVE
POSITIVE
NEGATIVE
 
 
84% 0f HPV positive women are smokers.This shows that there is a 
definite relation between smoking and HPV infection. 
 
 62
 
 
PREVIOUS HISTORY OF STD: 
 
TABLE 17 
                                         HPV TEST 
PAST H/O STD POSITIVE NEGATIVE 
PRESENT 25 7 
ABSENT 8 10 
 
75% of women who test positive for HPV had a past h/o one or more 
episodes of Reproductive tract infection. 
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0
5
10
15
20
25
+VE -VE
H/OSTD+
H/OSTD-
 
 
 
 
 
 
 
 
HPV IN HIGH AND LOW GRADE LESIONS. 
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0  
TABLE 18 
                                                 HPV TEST 
 
COLPOSCOPY NEGATIVE POSITIVE 
LSIL 17 24 
HSIL 0 9 
TOTAL 17 33 
 
 
Almost 100% of HSIL lesions show positive for HPV infection and 60% 
of LSIL lesions show positive for HPV infection. 
COLPOSCOPY
HSILLSIL0 
Count
30 
20 
10 
 
HPV TESTING
NEGATIVE
POSITIVE
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COMPOSITE TABLE SHOWING CO-FACTORS OF HPV LEADING 
ON TO PRECANCEROUS LESION OF CERVIX: 
 
P Value showing significance 
. 
 
TABLE 19 
HPV 
positivity 
Colposcopic 
lesions 
Past h/o 
STD 
Smoking Educatio
n 
SES Age at 
marria
ge 
Age  
group 
 66
33 0.017 0.049 <0.005 0.001 <0.001 <0.005 0.048 
 
 
This table shows the relative significance associated with HPV in causing 
pre cancerous lesions of cervix.This helps us in knowing the proportion of 
exposure and prevention.Thus Cancer cervix  can be prevented by 
improving the SES ,Health education regarding early screening 
methods,appropriate treatment of SIL of cervix,avoiding tobacco and 
getting married >21 years.   
 
 
DISCUSSION 
 
HPV and Age group 
This study is mainly conducted in reproductive age group between 25 and 35 
years.The peak incidence of HPV infection is between 28 and 30 years.The 
peak age group in this study correlated well with the study conducted by 
Cherian Verghese in 2000. 
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The ICPO community based study on 2073 married women in Alipur Delhi 
showed a peak prevelance in the age group 25 to 29 years. 
 
Grodione et al in his study of 2342 population documented an incidence of 
HPV in the age group 17 -25 years.Cherian Verghese of Kerala reported the 
peak age prevalence at 30years of age. 
 
 
 
 
EDUCATION AND HPV 
 
Education influences screening behavior through its effects on income and 
through its association with individual knowledge about cancer screening. The 
health-seeking behavior of many of the women in this setting is guided by 
traditional notions of ill health; many of them are not sure about the healing 
provided by modern medicine. Thus, communication problems that arose 
from differences among conceptions of health may also have contributed to 
the association between low levels of education and reduced participation. Ref 
Bradley J, Risi L, Denny L. Widening the cervical cancer screening net in a 
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South African township: who are the underserved? Health Care Women Int 
2004; 25:227-41 
 
Gwande et al studied  abouy the HPV status in under developed  areas and 
stated that it is a disease of poor educational status. 
Verghese et al also concluded this  in his study.  
HPV AND SOCIO ECONOMIC STATUS 
Low socio economic status is recognized as a risk factor for many problems 
including HPV infection.Women with low socio economic status have limited 
income ,restricted acsess to health care services,poor nutrition and a low level 
of issues about health care services and preventive behaviour.My study 
included women of low SES and hence icreased incidence. 
Sanjos et al who conducted a study in Madhya Pradesh in 1997 found 
a60%Decrease of prevelance of HPV  among upper SES. 
Gwande et al in 1998 in his study detected that Poor genital hygiene prevalent 
among low SES  is a risk factor for HPV. 
Dutta et al 1990 and Verghese etal 1999 also found HPV prevelance to be 
increased among low SES. 
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PARITY AND HPV 
HPV infection rate is high among women with increased parity. Pooled data 
from 8 case control studies from various continents show that as parity 
increases the HPV infection rate increases.The possibilities includes hormonal 
factors and trauma caused by delivery. 
 
Cherian Verghese in 2000 in his study has comparatively showed increased 
incidence in higher parities compared to lower parities. 
Fife et al in 1999 had shown increased prevelance of HPV among pregnant 
women , however only 20% of the infection continues to persist. 
Anna R Guiliano et al in his study had shown there is increased incidence of 
HPV as the parity increases. 
CONTRACEPTION 
 
In June 2000, the National Institutes of Health (NIH), in collaboration with the 
Centers for Disease Control and Prevention (CDC), the Food and Drug 
Administration (FDA), and the United States Agency for International 
Development (USAID), convened a workshop to evaluate the published 
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evidence establishing the effectiveness of latex male condoms in preventing 
STDs, including HIV. A summary report from that workshop was completed 
in July 2001 which says that condom use prevents HPV infection to some 
extent. 
 
Present study shows a comparatively less incidence of HPV infection among 
condom users. 
 Cherian Verghese in his study has documented a Very low incidence of HPV 
infection  among barrier contraceptives. 
Hippelianen et al in 1993 in his study had  said that Population with non 
condom users show more incidence of HPV  
AGE OF 1st SEXUAL INTERCOURSE AND HPV 
Earlier is the age of marriage there is increased incidence of HPV infection 
because the transformation zone is exposed very much in the ecto cervix 
which has cells of increased multiplicity rate. 
The National Health and Nutritional Examination Survey. NHANES was 
conducted from 1991-1994 by the National Center for Health Statistics and 
CDC using a complex, stratified, multistage probability cluster design in a 
sample population about the association between early age at first 
intercourse,and HPV infection.The study says that HPV infection rate is 
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increased among women of early age of 1st intercourse.The probable reasons 
given being it is a is a measure of lifetime rather than recent exposure. 
Ref Journal of infectious diseases 
11.15.02; Vol. 186; No. 10: P. 1396-1402; Katherine M. Stone; Kevin L. 
Karem; Maya R. Sternberg; Geraldine M. McQuillan; Alysia D. Poon; 
Elizabeth R. Unger; William C. Reeves 
 
 
Present study shows a high incidence of HPV among women who marry less 
than 20 years , which is very much documented in other studies coducted by 
Elstrom et al in 1996 and  Cherian Verghese in 2000. 
 
INCIDENCE OF HPV IN HIGH AND LOW GRADE LESIONS: 
HPV infection is sexually transmitted, affects the immature metaplastic cells 
of uterine cervix and, in an unknown proportion, results in squamous 
intraepithelial lesion (SIL) of differing severity was the report given by 
National Health Research Institutes, Taiwan, who conducted a A Multi-Center 
Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal 
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Follow-Up of LSIL Cases of cervix. An average estimation holds that about 
60% of low grade SIL will regress, 30% will persist, 10% will progress to 
high grade lesions and less than 1% becomes invasive lesions. 
Present study showed a high rate of incidence among HSIL (100%) and LSIL 
(60%) which is very much documented in many of the studies. 
Verghese et al showed 100% incidence of HPV in HSIL and 33.3% in LSIL. 
Van den brew  etal in his stidy has demonstrated 100% incidence of HPV in 
squamous intra epithelial lesions. 
Clavel et al  had shown a 100% incidence of HPV in high grade cervical 
lesions. 
Elfgren et al in his study of  squamous intra epithelial lesions 
Had shown84.8% of SIL showed HPV +vity and 28% of that lesions show 
persistence . 
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SMOKING AND HPV INFECTION. 
 
A prospective study was conducted about the association between smoking 
and HPV  by Aline Simen-Kapeu, Vesa Kataja, Merja Yliskoski, Kari 
Syrjänen, Joakim Dillner, Pentti Koskela, Jorma Paavonen and Matti 
Lehtinen in 2008 among 191 HPV infected samles which says that Smoking 
impairs the antibody response against HPV and hence their HPV positivity 
status is maintained for a long time.Ref Scandinavian Journal of Infectious 
Diseases2008, Vol. 40, No. 9, Pages 745-751 
                                    
In the new study, Gunnell and colleagues underwent cervical screening of 
146,104 women in a region of Sweden between 1969 and 1995. The study 
authors wrote that there appears to be a "synergistic" relationship between 
heavy smoking and high levels of a specific strain of HPV. 
Current smokers who had signs of HPV infection at the time of their first Pap 
smear were more than 14 times more likely to show signs of precancerous 
lesions than current smokers who weren't infected. 
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And heavy smokers who had high levels of HPV when first tested were 27 
times more likely to have precancerous lesions. Among nonsmokers, however, 
high HPV levels only raised their risk by six times. 
Gunnell said that cigarette smoke affect the immune system. Both smoking 
and HPV affect molecules known as cytokines, which control tumor growth, 
he said.Ref Anthony Gunnell, M.A.Sc., researcher, Karolinska Institutet, 
Stockholm, Sweden; November 2006, Cancer Epidemiology, Biomarkers & 
Prevention 
Sikstom et al1995 said that smoking is an important risk factor for HPV and 
the odds ratio associated was 1.4. 
PREVIOUS H/O STD: 
 
HPV infection rate is increased among women with a past h/o STD. 
John W. Sellors, Tina L. Karwalajtys, Janusz Kaczorowski, James B. 
Mahony, Alice Lytwyn, Sylvia Chong, Joanna Sparrow, Attila Lorincz, and 
The Survey of HPV in Ontario Women (SHOW) Group studied about the 
Incidence, clearance and predictors of human papillomavirus infection in 
women. 
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Incident infection with carcinogenic HPV was highest in women aged 25-29 
years, and risk factors were consistent with a h/o sexually transmitted 
infection in the past. Also a large proportion of the women who were HPV-
positive appeared to have cleared the infection after one year. 
Ref CMAJ. 2003 February 18; 168(4): 421–425 
 
My study showed a 75% of HPV positive rate with a previous H/O STDS. 
 
 
 
 
 
 
 
 
 
 
 
 
 76
HPV INFECTION RATE AMONG VARIOUS RISK FACTORS IN 
PRESENT STUDY AND OTHER STUDY: 
 PRESENT STUDY CHERIAN VERGHESE 
2000 
AGE GROUP 28 TO 30 YEARS 30 YEARS 
PARITY MULTI PARITY P2,P3 ↑INCIDENCE 
EDUCATION ILLITERATE AND LESS 
THAN PRIMARY SCHOOL 
↑ IN ILLITERATES 
SES LOW SES LOW SES 
CONTRACEPTION BARRIER 
CONTRACEPTIVES ARE 
SOME WHAT PROTECTIVE 
↓INCIDENCE  
IN BARRIER USERS 
SMOKING INCREASED AMONG 
SMOKERS 
↑ IN 
SMOKERS 
PAST H/O STD 75% HAVE H/O STD 80% HAVE H/O STD 
LSIL 60% SHOW POSITIVE 33.3% +VE 
HSIL 100% SHOW POSITIVE 100% +VE 
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FOLLOW UP 
All the HSIL and LSIL  lesions are biopsied 
 
                            Biopsy 
 
                       1   CIN3                  LLETZ  followed by Hysterectomy 
 
HSIL9            5 Mod Dysplasia   LLETZ and colposcopy every 6                                           
                                                                                                         months 
                       3 Mild dysplasia     cryotherapy and  Colposcopy every 6                                 
                                                                                                         months 
 
                                                                                                                    
 
                30  Inflammatory    Colposcopy every 6 months 
                                           
LSIL41   7Cases  Mild dysplasia   cryotherapy colposcopy       
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              4 Moderate dysplasia   LLETZ Colposcopy every 6 months 
These women of moderate dysplasia are in younger age group who want 
to preserve fertility. 
 
 
 
 
SUMMARY 
Although oncogenic HPV infection has been established as a causative factor 
of the precursors of cancer cervix as well as their progression to higher grade 
and eventually to malignancy, there are some other predisposing factors which 
play a substantive role in the causation and progression of these lesions. This 
study has tried to delineate these risk factors in cases of cervical dysplasia. 
This study is a prospective study conducted in a sample of 50 women in the 
reproductive age group . Women with  LSIL AND HSIL Lesions are selected 
,cervical samples are taken from them and couriered to Renu Diagnostics 
lab.HPV infection is detected by HC 2 technique. It is an In vitro nucleic Acid 
Hybridization Microplate Assay with Amplification using Microplate 
chemiluminescene for the Qualitative Detection of 13 High-Risk types of 
human papillomavirus (HPV) DNA in cervical Specimen’s.. 
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The results are coded in RLU. HPV infection showed higher incidence among 
28to30 years of age, among low SES and among illiterates. 100% of HSIL 
showed HPV infection and 60% of LSIL showed positive infection. 
HPV infection shows higher incidence among low social status where the 
genital hygiene is poor and among illiterate women who have a very poor 
knowledge about sources of prevention.Women of low SES also get married 
soon and have decreased birth spacing which increases the incidence.  
Following these women 73% of these lesions were inflammatory ,treated with 
antibiotics and followed up with colposcopy every 6 months.9 cases found to 
be moderate dysplasia and treated by LLETZ.10 cases found to be mild 
dysplasia ,Cryotherapy was done in these women. 1 lesion turned out to be 
CIN3 and proceeded with TAH. 
 
CONCLUSION 
 
Accumulated evidence based on etiologic associations and the differential 
world pattern points to cervical cancer being a preventable disease. Sexual 
hygiene and the use of barrier contraception (condom) may largely achieve 
this objective but there is a need for long-term education and acceptance. 
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Improvements in socio-economic standards would automatically reduce 
morbidity and mortality but this again is a long-term process.  
Primary prevention, then, involves the education of a large segment of the 
population, especially the high risk groups,  about sexual hygiene, barrier 
contraception and control of HPV infection.  
Secondary prevention assumes vital importance in the context of the hurdles 
in implementing primary prevention methods. In a large country such India 
with a large, growing population and limited resources, population screening 
by Pap smear is neither pragmatic nor cost-effective. It is thus essential that 
we evolve our own strategies.  
Women with an abnormal cervix should have additional studies including: 
Pap smear, biopsy, colposcopy and HPV DNA testing wherever possible. 
 
 
 
 
                                           ANNEXURE 
 
PROFORMA 
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NAME  `: 
 
AGE   : 
 
S.NO   : 
 
ADDRESS  : 
 
OCCUPATION : 
 
SE CLASS  : 
 
MENSTRUAL HISTORY 
 
AGE AT MENARCHE       Years 
 
CYCLE  / DAYS 
 
LAST MENSTRUAL PERIOD 
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MARITAL HISTORY: 
 
AGE OF MARRIAGE/FIRST INTERCOURSE   Years    
 
LIVING WITH HUSBAND 
 
COITAL HISTORY 
 
FREQUENCY OF COITUS  
 
NO.OF SEXUAL PARTNERS 
 
USE OF CONDOMS 
 
OBSTETRIC HISTORY 
 
PARTY  
 
LAST CHILD BIRTH 
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STERLIZED 
 
 
PERSONAL HISTORY 
 
H/O OCP 
 
H/O  SMOKING 
 
 
 
PAST HISTORY: 
 
H/O STD’s IN THE PAST 
 If Any Number Of Times 
 
H/O CRYOTHERAPY DONE 
 
H/O RADIOTHERAPY IN THE PAST 
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H/O CHEMOTHERAPY IN THE PAST  
 
FAMILY HISTORY: 
 
H/O MALIGNANICES IN THE FAMILY MEMBERS 
 
CLINICAL EXAMINATION: 
 
BUILD AND NOURISHMENT 
 
 
LOCAL EXAMINATION: 
 
SPECULUM EXAMINATION 
 
VAGINA 
 
CERVIX 
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ANY DISCHARGE 
 
BIMANUAL PELVIC EXAMINATION: 
 
CERVIX  
: 
UTERUS 
 
FORNICES 
 
COLPOSCOPIC FINDING: 
 
CYTOLOGICAL STUDY OF CERVIX BRUSINGS 
 
HUMAN PAPILLOMA VIRUS TESTING BY HC II: 
 
 
OUTCOME   :              POSTIVE            
 NEGATIVE 
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ADVICE: 
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SL.NO age 
age at 
menarche 
age at 1 st 
esx. Ic parity lcb contracep colpos 
hpv 
testing
ses 
group 
edu 
group smoking h/Ostd
1 35 12 20 3 11 1 1 1 2 1 3 1
2 30 13 22 2 8 1 1 1 1 3 2 1
3 30 14 18 2 8 1 1 0 1 1 2 1
4 29 13 21 2 6 1 2 1 2 2 2 1
5 34 14 19 3 11 1 1 0 2 1 3 1
6 30 15 20 2 5 1 1 1 1 2 2 1
7 28 14 22 2 4 1 2 1 2 3 2 1
8 25 16 20 1 4 3 1 0 3 2 2 0
9 29 15 22 2 3 1 2 1 1 1 1 0
10 30 14 18 2 9 1 1 1 1 1 2 1
11 32 16 21 2 7 2 1 0 1 1 2 1
12 29 15 20 2 5 1 1 1 2 3 2 1
13 35 14 24 3 8 1 1 1 2 2 2 1
14 32 16 22 3 6 1 1 1 3 1 2 1
15 30 13 20 2 5 1 1 0 1 3 2 0
16 29 14 21 2 2 1 1 1 3 2 1 1
17 31 14 25 2 2 1 1 0 1 1 1 0
18 26 16 23 1 2 4 1 1 2 2 1 1
19 28 12 21 2 3 1 1 0 2 2 1 1
20 34 13 25 2 4 1 1 1 3 1 2 1
21 27 14 18 2 4 1 1 0 2 1 2 1
22 34 13 20 2 5 1 1 1 3 2 2 1
23 28 15 23 2 2 1 1 1 2 2 1 1
24 30 13 19 2 5 4 2 1 2 2 2 0
25 35 12 20 3 11 1 1 1 2 1 3 1
26 30 13 22 2 8 1 1 1 1 3 2 1
27 30 14 18 2 8 1 1 0 1 1 2 1
28 29 13 21 2 6 1 2 1 2 2 2 1
29 34 14 19 3 11 1 1 0 2 1 3 0
30 30 15 20 2 5 1 1 1 1 2 2 0
31 28 14 22 2 4 1 2 1 2 3 2 1
32 25 16 20 1 4 4 1 0 3 2 2 1
33 29 15 22 2 3 3 2 1 1 1 1 0
34 30 14 18 2 9 1 1 1 1 1 2 1
35 32 16 21 2 7 1 1 0 1 1 2 0
36 29 15 20 2 5 1 1 1 2 3 2 1
37 35 14 24 3 8 1 1 1 2 2 2 1
38 32 16 22 3 6 1 1 1 3 1 2 1
39 30 13 20 2 5 1 1 0 1 3 2 1
40 29 14 21 2 2 1 1 1 2 2 1 1
41 31 14 25 2 2 1 1 0 1 1 1 1
42 26 16 23 1 2 2 1 1 2 2 1 0
43 28 12 21 2 3 1 1 0 2 2 1 1
44 34 13 25 2 4 1 1 1 3 1 2 1
45 27 14 18 2 4 1 1 0 2 1 2 1
46 34 13 20 2 5 1 1 1 3 2 2 1
47 28 15 23 2 2 4 1 1 2 2 1 0
48 30 13 19 2 5 1 2 1 2 2 2 1
49 32 12 18 3 7 1 2 1 2 2 2 0
50 30 13 20 2 5 1 1 0 2 2 2 1
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EDUCATION 
3- 5th to 10th STD   2-<5th STD   1-NIL 
SES 
1income ≥ Rs 3000 PM  2 income Rs2000PM   3 income Rs1500PM 
SMOKING  
1Tobacco chewers  2 Passive smoking 
3 Active smoking 
H/O STD 
Present 1  Absent 0 
HPV TESTING                       
Positive 1  Negative 0 
COLPOSCOPY 
LSIL 1   HSIL 2 
CONTACEPTION                 
 
1 PS 
2 BARRIER 
3 OCP 
4 IUCD 
SL.NO age 
age at 
menarche 
age at 1 st 
esx. Ic parity lcb contracep colpos 
hpv 
testing 
ses 
group 
edu 
group smoking h/Ostd
1 35 12 20 3 11 1 1 1 2 1 3 1 
2 30 13 22 2 8 1 1 1 1 3 2 1 
3 30 14 18 2 8 1 1 0 1 1 2 1 
4 29 13 21 2 6 1 2 1 2 2 2 1 
5 34 14 19 3 11 1 1 0 2 1 3 1 
6 30 15 20 2 5 1 1 1 1 2 2 1 
7 28 14 22 2 4 1 2 1 2 3 2 1 
8 25 16 20 1 4 3 1 0 3 2 2 0 
9 29 15 22 2 3 1 2 1 1 1 1 0 
10 30 14 18 2 9 1 1 1 1 1 2 1 
11 32 16 21 2 7 2 1 0 1 1 2 1 
12 29 15 20 2 5 1 1 1 2 3 2 1 
13 35 14 24 3 8 1 1 1 2 2 2 1 
14 32 16 22 3 6 1 1 1 3 1 2 1 
15 30 13 20 2 5 1 1 0 1 3 2 0 
16 29 14 21 2 2 1 1 1 3 2 1 1 
17 31 14 25 2 2 1 1 0 1 1 1 0 
18 26 16 23 1 2 4 1 1 2 2 1 1 
19 28 12 21 2 3 1 1 0 2 2 1 1 
20 34 13 25 2 4 1 1 1 3 1 2 1 
21 27 14 18 2 4 1 1 0 2 1 2 1 
22 34 13 20 2 5 1 1 1 3 2 2 1 
23 28 15 23 2 2 1 1 1 2 2 1 1 
24 30 13 19 2 5 4 2 1 2 2 2 0 
25 35 12 20 3 11 1 1 1 2 1 3 1 
26 30 13 22 2 8 1 1 1 1 3 2 1 
27 30 14 18 2 8 1 1 0 1 1 2 1 
28 29 13 21 2 6 1 2 1 2 2 2 1 
29 34 14 19 3 11 1 1 0 2 1 3 0 
30 30 15 20 2 5 1 1 1 1 2 2 0 
31 28 14 22 2 4 1 2 1 2 3 2 1 
 32 25 16 20 1 4 4 1 0 3 2 2 1 
33 29 15 22 2 3 3 2 1 1 1 1 0 
34 30 14 18 2 9 1 1 1 1 1 2 1 
35 32 16 21 2 7 1 1 0 1 1 2 0 
36 29 15 20 2 5 1 1 1 2 3 2 1 
37 35 14 24 3 8 1 1 1 2 2 2 1 
38 32 16 22 3 6 1 1 1 3 1 2 1 
39 30 13 20 2 5 1 1 0 1 3 2 1 
40 29 14 21 2 2 1 1 1 2 2 1 1 
41 31 14 25 2 2 1 1 0 1 1 1 1 
42 26 16 23 1 2 2 1 1 2 2 1 0 
43 28 12 21 2 3 1 1 0 2 2 1 1 
44 34 13 25 2 4 1 1 1 3 1 2 1 
45 27 14 18 2 4 1 1 0 2 1 2 1 
46 34 13 20 2 5 1 1 1 3 2 2 1 
47 28 15 23 2 2 4 1 1 2 2 1 0 
48 30 13 19 2 5 1 2 1 2 2 2 1 
49 32 12 18 3 7 1 2 1 2 2 2 0 
50 30 13 20 2 5 1 1 0 2 2 2 1 
 
             
EDUCATION 
3- 5th to 10th STD   2-<5th STD   1-NIL 
SES 
1income ≥ Rs 3000 PM  2 income Rs2000PM   3 income Rs1500PM 
 
SMOKING  
1Tobacco chewers  2 Passive smoking 
3 Active smoking 
 
H/O STD 
Present 1  Absent 0 
HPV TESTING                       
Positive 1  Negative 0 
 
COLPOSCOPY 
LSIL 1   HSIL 2 
 
CONTACEPTION                 
1 PS 
2 BARRIER 
3 OCP 
4 IUCD 
 
